home / stock / sngx / sngx news

SNGX News and Press, Soligenix Inc. From 12/03/19

Stock Information
Company Name: Soligenix Inc.
Stock Symbol: SNGX
Market: NASDAQ
Website: soligenix.com
Menu
SNGX SNGX Quote SNGX Short SNGX News SNGX Articles SNGX Message Board
Get SNGX Alerts

News, Short Squeeze, Breakout and More Instantly...
SNGX - Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

PRINCETON, N.J. , Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed...
SNGX - Soligenix to Present at the PCG Spotlight Series Conference

PRINCETON, N.J. , Nov. 18, 2019 /PRNewswire/ --  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today tha...

SNGX - NetworkNewsBreaks - Soligenix, Inc. (NASDAQ: SNGX) Announces Recent Accomplishments and Q3 2019 Financial Results

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the quarter ended September 30, 2019. “We...

SNGX - Soligenix EPS misses by $0.01, beats on revenue

Soligenix (NASDAQ: SNGX ): Q3 GAAP EPS of -$0.14 misses by $0.01 . More news on: Soligenix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SNGX - Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

PRINCETON, N.J. , Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its r...

SNGX - Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference

PRINCETON, N.J. , Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Danie...

SNGX - Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition

PRINCETON, N.J. , Oct. 24, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Unite...
SNGX - Catalyst Watch: Soligenix Inc.'s SGX301 and SGX942 Upcoming Data Release Can Change the CTCL and Oral Mucositis Treatment Landscape

Miami Beach, Florida--(Newsfile Corp. - October 22, 2019) - There are two things that developing biotechs need for success. First, they need a good drug. Second, they need cash to fund clinical trials. Soligenix has both (NASDAQ: SNGX). Combined, the two may offer Soligenix investors a near-...

SNGX - Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer

Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches...

SNGX - Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada

PRINCETON, N.J. , Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief S...
Previous 10 Next 10